Significance: Aggregation and cell-to-cell spread of TDP-43 are thought to underlie many cases of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Additionally, the aging process and environmental toxins stimulate excessive generation of reactive oxygen and nitrogen species (ROS/RNS), thus contributing to the pathological processes of these neurodegenerative diseases. Here, we show that nitric oxide (NO)-related species promote TDP-43 proteinopathy in cell-based and animal models of FTD/ALS via S-nitrosylation of TDP-43 at critical cysteine residues that facilitate disulfide bond formation and abnormal aggregation of the protein. In contrast, expression of nonnitrosylatable mutant TDP-43 ameliorates TDP-43 aggregation, RNA binding, and cell toxicity. Thus, our study provides mechanistic insight into the ROS/RNS-induced TDP-43 proteinopathy and neurotoxicity observed in FTD/ALS patients.
27 February 2025 in Proceedings of the National Academy of Sciences
CAMP response element-binding protein (CREB)-regulated transcription coactivator 1 (CRTC1) plays an important role in synaptic plasticity, learning, and long-term memory formation through the regulation of neuronal activity-dependent gene expression, and CRTC1 dysregulation is implicated in Alzheimer’s disease (AD). Here, we show that increased S-nitrosylation of CRTC1 (forming SNO-CRTC1), as seen in cell-based, animal-based, and human-induced pluripotent stem cell (hiPSC)-derived cerebrocortical neuron-based AD models, disrupts its binding with CREB and diminishes the activity-dependent gene expression mediated by the CRTC1/CREB pathway. We identified Cys216 of CRTC1 as the primary target of S-nitrosylation by nitric oxide (NO)-related species. Using CRISPR/Cas9 techniques, we mutated Cys216 to Ala in hiPSC-derived cerebrocortical neurons bearing one allele of the APP Swe mutation (AD-hiPSC neurons). Introduction of this nonnitrosylatable CRTC1 mutant rescued defects in AD-hiPSC neurons, including decreased neurite length and increased neuronal cell death. Additionally, expression of nonnitrosylatable CRTC1 in vivo in the hippocampus rescued synaptic plasticity in the form of long-term potentiation in 5XFAD mice. Taken together, these results demonstrate that formation of SNO-CRTC1 contributes to the pathogenesis of AD by attenuating the neuronal activity-dependent CREB transcriptional pathway, and suggests a therapeutic target for AD.